Clinical significance of the pretreatment C-reactive protein-albumin-lymphocyte (CALLY) index in colorectal cancer patients: a meta-analysis.
메타분석
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
362 patients with colorectal cancer, were included in the meta-analysis.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Our evidence suggests that the pretreatment CALLY index holds potential as a valuable biomarker to predict clinical outcomes for patients with colorectal cancer. [SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-026-15557-7.
[BACKGROUND] The C-reactive protein-albumin-lymphocyte (CALLY) index, which is devised to evaluate the inflammatory, immune, and nutritional status of patients, has emerged as a potentially valuable p
- 95% CI 0.41–0.81
- HR 0.58
- 연구 설계 meta-analysis
APA
Pang H, Dai F, et al. (2026). Clinical significance of the pretreatment C-reactive protein-albumin-lymphocyte (CALLY) index in colorectal cancer patients: a meta-analysis.. BMC cancer, 26(1), 212. https://doi.org/10.1186/s12885-026-15557-7
MLA
Pang H, et al.. "Clinical significance of the pretreatment C-reactive protein-albumin-lymphocyte (CALLY) index in colorectal cancer patients: a meta-analysis.." BMC cancer, vol. 26, no. 1, 2026, pp. 212.
PMID
41530698 ↗
Abstract 한글 요약
[BACKGROUND] The C-reactive protein-albumin-lymphocyte (CALLY) index, which is devised to evaluate the inflammatory, immune, and nutritional status of patients, has emerged as a potentially valuable prognostic biomarker in diverse malignancies. The aim of this study is to conduct a systematic investigation into the correlation between the pretreatment CALLY index and clinical outcomes in patients with colorectal cancer.
[METHODS] A comprehensive systematic literature search was carried out using electronic databases, including Web of Science, PubMed, CNKI and Embase. The search spanned from inception to July 1, 2025, with an update on September 20, 2025. The primary endpoints were survival outcomes and postoperative complications, while the secondary outcomes were clinicopathological features. This meta-analysis has been registered with PROSPERO (CRD420251156757).
[RESULTS] A total of ten studies, involving 7,362 patients with colorectal cancer, were included in the meta-analysis. The pooled findings indicated that patients in the high CALLY group demonstrated significantly better overall survival (Hazard ratio [HR] = 0.62; 95% confidence interval [CI]: 0.53–0.73; I² = 69%), better disease-free survival (HR = 0.58; 95% CI: 0.41–0.81; I² = 84%), and a lower risk of postoperative complications (Odds ratio [OR] = 0.55; 95% CI: 0.38–0.81; I² = 29%) compared to those in the low CALLY group. Moreover, a high CALLY index was significantly associated with a lower percentage of T4 tumors and a lower proportion of poorly differentiated histology.
[CONCLUSIONS] Our evidence suggests that the pretreatment CALLY index holds potential as a valuable biomarker to predict clinical outcomes for patients with colorectal cancer.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-026-15557-7.
[METHODS] A comprehensive systematic literature search was carried out using electronic databases, including Web of Science, PubMed, CNKI and Embase. The search spanned from inception to July 1, 2025, with an update on September 20, 2025. The primary endpoints were survival outcomes and postoperative complications, while the secondary outcomes were clinicopathological features. This meta-analysis has been registered with PROSPERO (CRD420251156757).
[RESULTS] A total of ten studies, involving 7,362 patients with colorectal cancer, were included in the meta-analysis. The pooled findings indicated that patients in the high CALLY group demonstrated significantly better overall survival (Hazard ratio [HR] = 0.62; 95% confidence interval [CI]: 0.53–0.73; I² = 69%), better disease-free survival (HR = 0.58; 95% CI: 0.41–0.81; I² = 84%), and a lower risk of postoperative complications (Odds ratio [OR] = 0.55; 95% CI: 0.38–0.81; I² = 29%) compared to those in the low CALLY group. Moreover, a high CALLY index was significantly associated with a lower percentage of T4 tumors and a lower proportion of poorly differentiated histology.
[CONCLUSIONS] Our evidence suggests that the pretreatment CALLY index holds potential as a valuable biomarker to predict clinical outcomes for patients with colorectal cancer.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-026-15557-7.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (3)
- TIP-20, a novel feline McDonough sarcoma-like tyrosine kinase 3 inhibitor with potent antileukemia activity.
- Canertinib as an FLT3 Inhibitor with Potent Activity Against FLT3-Mutated and AC220-Resistant Acute Myeloid Leukemia.
- Integrated liquid biopsy model for predicting metastasis and guiding PD-1 therapy in esophageal squamous cell carcinoma.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Opposing prognostic roles of tumor-associated and circulating MMP8 in colorectal cancer.
- Copper-enriched zinc peroxides induced cuproptosis through concurrent metabolic and oxidative dysregulation for boosting immunotherapy in colorectal cancer.
- Editorial: Altered metabolic traits in gastro-intestinal tract cancers, volume II.
- Macrophage deficiency discordantly regulated tumor growth and metastasis through increased thrombospondin-1 production.
- Time-Resolved Oxygen Dynamics Reveals Redox-Selective Apoptosis Induced by Cold Atmospheric Plasma in HT-29 Colorectal Cancer Cells.
- System-Wide Implementation of Colorectal Cancer Screening in a Value-Based Care Setting.